Company news
Ataibeckley Inc. (NASDAQ:ATAI) news
Every Ataibeckley Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
October 17, 2022
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
October 11, 2022
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
October 4, 2022
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
October 3, 2022
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
September 26, 2022
atai Life Sciences to Participate in September Investor Events
September 5, 2022
atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital
August 14, 2022
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
August 14, 2022
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update
July 31, 2022
atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
June 29, 2022
Stephen Bardin to Join atai Life Sciences as CFO Designate
June 16, 2022
atai Life Sciences to Participate in Upcoming June Healthcare Conferences
June 15, 2022
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
May 15, 2022
CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update
May 4, 2022
atai Life Sciences to Announce First-Quarter 2022 Financial Results
May 3, 2022
atai Life Sciences to Participate in Upcoming April Investor Conference
April 18, 2022
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
March 29, 2022
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
March 22, 2022
atai Life Sciences to Participate in Upcoming March Investor Conferences
March 20, 2022
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
February 15, 2022
atai Life Sciences to Participate in Upcoming February Investor Conference
February 14, 2022
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
January 26, 2022
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
January 11, 2022
atai Life Sciences to Participate in Upcoming January Investor Conference
January 9, 2022
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics
December 15, 2021
Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements
December 14, 2021
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
December 13, 2021
atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index
December 12, 2021
atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai's supply chain
December 8, 2021
atai Life Sciences Increases its Ownership Position in COMPASS Pathways
November 28, 2021
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
November 14, 2021
atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
November 7, 2021
atai Life Sciences to Participate in Upcoming November Investor Conferences
November 4, 2021
atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia
October 31, 2021
atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change
October 18, 2021
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
October 10, 2021
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
September 14, 2021
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
September 13, 2021
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
September 8, 2021
atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update
August 15, 2021
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions
August 11, 2021
atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
August 8, 2021
atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference
August 5, 2021
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
July 27, 2021
atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
July 6, 2021
atai Life Sciences Announces Pricing of Upsized Initial Public Offering
June 16, 2021